Ownership Summary
Recent 13F filings as of December 2025 show that 7 institutional investors hold a position in Northwest Biotherapeutics Inc (OTC:NWBO).
- These investors collectively held 0.0% of the company's total shares outstanding in December 2025, up from 0.0% in September 2025.
- Quarterly data indicates a 9.49% shift in institutional share volume, and the annual owner count reflects a decrease of 22.22%.
- Of these 7 institutional investors, 2 increased their holdings in Northwest Biotherapeutics, while 0 of them reduced positions, and 5 investors maintained their exposure.
- Collectively, institutional investors increased their stake in Northwest Biotherapeutics to 207.59K shares as of December 2025, a change that is up by 18.00K shares quarter on quarter and down 7.28K shares year over year.
- With 80.57K shares, VSM Wealth Advisory, LLC commands the largest institutional position in Northwest Biotherapeutics as of December 31, 2025, equating to 0.01% of the company.
- Among the most significant buyers of Northwest Biotherapeutics during December 2025 were VSM Wealth Advisory, LLC (15.00K), Ethos Financial Group, LLC (3.00K).
- The top 7 institutional holders of Northwest Biotherapeutics for the quarter ending December 2025 included VSM Wealth Advisory, LLC (80.57K), Opus Capital Group, LLC (60.15K), Ethos Financial Group, LLC (28.35K), Williams Jones Wealth Management, LLC. (27.00K), ADVISORS MANAGEMENT GROUP INC /ADV (10.27K), Coston, McIsaac & Partners (1.00K), HANTZ FINANCIAL SERVICES, INC. (250).